Boehringer Ingelheim

This study gave a single infusion of spesolimab to 39 people in China with a severe skin disease called generalized pustular psoriasis (GPP) during a flare-up. Participants had no other treatment options. The goal was to control the flare and monitor side effects over about 4 mon…

This early-stage trial tested a new drug called BI 836880 in 29 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. The drug was given through an IV, and researchers monitored …

This study tested a medicine called spesolimab in 27 adults with Crohn's disease who also have fistulas near the anus. Participants received either the drug or a placebo every 4 weeks for 24 weeks. The goal was to see if the drug helps close fistulas and understand how it works. …

This study tested an experimental pill, BI 1015550, in over 1,100 adults with idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease. Participants took either the drug or a placebo twice daily for at least a year, while some continued their usual IPF medications…

This study tested a new medicine, BI 764198, in 67 adults with a kidney disease called FSGS. The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage. Participants took either the drug or a placebo daily for 12 weeks. The results help researchers…

This study tested two drugs, brigimadlin and ezabenlimab, in adults with advanced solid tumors. The first part found the safest dose, and the second part checks if the combination can shrink tumors. Participants take pills and get infusions every 3 weeks for up to 2 years, as lon…

This study tested an experimental drug called BI 655064 in 121 people with active lupus nephritis, a serious kidney complication of lupus. The goal was to see if adding this drug to standard treatment could improve kidney function after one year. Participants received one of thre…

This study tested a new tablet called BI 1291583 in 22 adults with cystic fibrosis and bronchiectasis (damaged airways). Participants took either the study drug or a placebo once daily for 12 weeks. The main goal was to check safety and side effects, not to cure the disease. Resu…

This study tracked 1,200 Japanese adults with chronic heart failure who took JARDIANCE tablets daily for a long time. Researchers monitored side effects like low blood sugar, dehydration, and kidney issues, as well as deaths and hospitalizations. The goal was to see how safe and …

This study tested an experimental drug called BI 655130 in 59 adults with palmoplantar pustulosis (PPP), a skin condition causing painful pus-filled blisters on the palms and soles. The goal was to see if the drug could reduce the severity of the rash and was safe compared to a p…

This study tested a new oral drug, afatinib, against a standard intravenous chemotherapy, methotrexate, in 340 adults with advanced head and neck cancer that had worsened after platinum-based treatment. The main goal was to see if afatinib could delay cancer growth better than me…

This study tested a combination of two drugs (BI 836880 and ezabenlimab) in adults with advanced lung cancer and other solid tumors. The first part found the safest dose, and the second part checked if the combo could shrink tumors. Participants received infusions every 3 weeks a…

This study tested a new medicine called survodutide (BI 456906) in 726 adults with overweight or obesity who had not been able to lose weight through diet alone. Participants received weekly injections of either survodutide or a placebo for about 76 weeks, along with diet and exe…

This study tested an experimental drug called BI 655130 in 51 adults with moderate to severe atopic dermatitis (eczema). Participants received either the drug or a placebo through an IV, and researchers measured changes in skin redness, thickness, and itching over 16 weeks. The g…

This early-stage study tested a new medicine called BI 3006337 in 64 adults who are overweight or have obesity and also have fatty liver disease. Participants received weekly injections of either the study drug or a placebo for about 4 months. The main goal was to see what dose i…

This study looked at whether atomoxetine, a medication for ADHD, can reduce impulsive behavior in adults aged 18 to 45 with moderate ADHD. Researchers measured impulsivity using questionnaires after a single dose and after two weeks of daily treatment. The goal was to see if the …

This early-stage trial tested the safety and how the body handles multiple rising doses of a new drug called BI 3810477. It involved 47 healthy adults aged 18 to 60. The study did not aim to treat any disease, but rather to gather important safety and drug-level information for f…

This study looked at how a new drug called BI 655130 enters the body when injected in different places (belly vs. thigh) and in different amounts. 48 healthy adults took part to help researchers understand the drug's levels in the blood. The goal was not to treat any disease, but…

This trial looked at how taking the experimental drug Zongertinib with or without food affects its absorption in the body. Sixteen healthy men each received a single dose under both conditions. The results will help determine the best way to take the medicine in future studies.

This study looked at whether taking multiple doses of the drug Iclepertin affects how the body processes a common birth control pill (Microgynon) in healthy women aged 18-35. Nineteen participants took the birth control pill with and without Iclepertin, and researchers measured d…

This study looked at how the experimental brain medicine iclepertin is processed in people with and without liver problems. About 29 adults took a single dose of the drug, and researchers measured its levels in the blood. The goal was to see if liver impairment changes how the bo…

This early-stage study tested a new drug called BI 425809 in 83 healthy men to see if it was safe and how the body handles it. Researchers gave single rising doses and compared different forms (liquid vs. tablet) and the effect of food. The goal was to gather safety data and unde…

This early-stage study tested the safety and how the body handles a new drug called BI 425809 in 96 healthy young and elderly volunteers. Participants took the drug as tablets once daily for 12 days, and researchers also compared taking it in the morning versus evening. The goal …

This study looked at how a new drug (BI 1015550) is absorbed in the body when given in different pill versions and with or without food. Twenty-four healthy adults took a single dose of each version in a random order. The goal was to compare the formulations, not to treat any dis…

This study looked at how a new drug called BI 3000202 affects the way the body handles two other medicines: rosuvastatin (used for cholesterol) and digoxin (used for heart conditions). Fourteen healthy adults took part. The goal was to see if BI 3000202 changes the levels of thes…

This early-stage study looked at how a new drug called BI 425809 changes the way the body processes four common medicines (midazolam, warfarin, omeprazole, and digoxin). Thirteen healthy men took these medicines alone and then again while also taking BI 425809. The goal was to se…

This study looked at how the body absorbs empagliflozin, a diabetes medication, when taken as a whole tablet versus dissolved in water and mixed with food. Fourteen healthy adults participated to compare the two methods. The results help doctors understand if the drug works the s…

This study followed 158 adults with chronic fibrosing interstitial lung disease (a type of lung scarring) who were starting the drug nintedanib. Researchers wanted to see if changes in lung function (measured by a breathing test called FVC) were linked to changes in cough and sho…

This study looked at how the antifungal drug fluconazole changes the way the body handles a single dose of BI 425809. Fifteen healthy men took BI 425809 alone and then again while also taking fluconazole. The goal was to measure drug levels in the blood to understand any interact…

This early-stage study tested a new drug called BI 3006337 in 36 healthy Japanese men to see if it is safe and how the body processes it. Participants received either a single shot or weekly shots for 6 weeks. The goal was to gather safety data and measure drug levels, not to tre…

This study looked at whether a new weight-loss drug (BI 456906) changes how the body processes three common drugs: bupropion, caffeine, and midazolam. It involved 34 healthy adults with overweight or obesity. Participants took the three drugs alone, then again while receiving wee…

This study looked at how taking multiple doses of an experimental drug (BI 1015550) changes the way the body absorbs and processes two approved lung medicines (nintedanib and pirfenidone). Fourteen healthy men aged 18 to 55 took part. The goal was purely to gather information on …

This early-stage study tested the safety and tolerability of a new drug called BI 1015550 in 42 healthy men. Participants received either single or multiple rising doses of the drug. The goal was to see if the drug was safe and how the body processes it, not to treat any disease.

This study looked at how a new cancer drug called zongertinib changes the way the body processes other medicines. It involved 32 healthy men who took zongertinib along with drugs like dabigatran (a blood thinner), rosuvastatin (cholesterol medicine), metformin (diabetes drug), an…

This study looked at how taking the drug BI 1015550 with or without food changes the amount of drug in the blood. Eighteen healthy adults took the drug twice—once after eating and once on an empty stomach—to compare the effects. The results will help doctors decide whether to tak…

This study looked at how the antibiotic rifampicin changes the way the body handles an experimental drug called BI 425809. Sixteen healthy men took a single dose of BI 425809 alone and then again after several days of rifampicin. The goal was to measure drug levels in the blood t…

This study tested two new versions of a tablet (BI 425809) against an older version to see how well the body absorbs each one. It involved 18 healthy adults aged 18 to 55. The goal was simply to compare the formulations, not to treat any disease.